Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|19|3428-3434

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.19, 2015-10, pp. : 3428-3434

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combined treatment with gemcitabine plus oxaliplatin shows encouraging efficacy in patients with relapsed or cisplatin-refractory germ cell tumours

By  

Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Everolimus for the treatment of pancreatic neuroendocrine tumors

By Feldmann Georg   Bisht Savita   Schütte Ute   Haarmann Jens   Brossart Peter  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 14, 2012-10 ,pp. : 2073-2084

Informa Healthcare

Access to resources Recommend Favorite

Emerging therapies for the treatment of patients with advanced neuroendocrine tumors

By Chan Jennifer A   Kulke Matthew H  

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 2, 2007-05 ,pp. : 253-270

Informa Healthcare

Access to resources Recommend Favorite

Neuroendocrine Tumors

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 7, 2009-07 ,pp. : 712-712

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

By Tsavaris Nicolas   Kosmas Christos   Skopelitis Helias   Gouveris Panagiotis   Kopteridis Petros   Loukeris Dioynissis   Sigala Frantzeska   Zorbala-Sypsa Alexandra   Felekouras Evangelos   Papalambros Efstathios  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 369-375

Springer Publishing Company

Access to resources Recommend Favorite